This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

PAUL TENG, M.D.

Arch Neurol Psychiatry. 1950;64(6):861-877.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

DURING the past two years, 13 patients with purulent meningitis have been treated with bacitracin. The organisms and their incidence were as follows: Staphylococcus, six cases; Streptococcus, two cases; Pneumococcus, one case; mixed organisms, two cases, and an unidentified gram-positive coccus, two cases (table 1).

STAPHYLOCOCCIC MENINGITIS

Of the group of six patients with staphylococcic meningitis, five are reported on in a separate article.¹ All these 6 patients were treated with bacitracin by the intrathecal or the intraventricular route, or by both routes whenever such a method was indicated. This therapy was supplemented by the intramuscular injection of bacitracin and other antibiotics when that seemed advisable. In every instance the causal organism was found to be resistant to penicillin, which, in fact, had previously been used in excessive amounts both by subarachnoid and by intramuscular injections, with no avail. After bacitracin therapy five patients recovered and one died. The . . . [Full Text PDF of this Article]

Author Affiliations
NEW YORK

From the Departments of Neurology and Neurosurgery, Mount Sinai Hospital.

Footnotes
The bacitracin used was supplied by the Commercial Solvents Corporation, Terre Haute, Ind.